{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:03:26Z","timestamp":1781013806525,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","award":["ESR-17-12847"],"award-info":[{"award-number":["ESR-17-12847"]}],"id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HR21C0198"],"award-info":[{"award-number":["HR21C0198"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C2091689"],"award-info":[{"award-number":["2022R1A2C2091689"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asan Institute for Life Sciences","award":["2024IF0023, 2024IP0076"],"award-info":[{"award-number":["2024IF0023, 2024IP0076"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11060-026-05643-y","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:31:03Z","timestamp":1779546663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1"],"prefix":"10.1007","volume":"178","author":[{"given":"Soojin","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyeong Hwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyery","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyosang","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-5734","authenticated-orcid":false,"given":"Hee Mang","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-2631","authenticated-orcid":false,"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"5643_CR1","unstructured":"Board TWCTE (2020) WHO Classification of Tumours Soft Tissue and Bone Tumours. 5th edn. IARC Press: Lyon, France"},{"issue":"1","key":"5643_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/dermatopathology10010001","volume":"10","author":"NS Nagrani","year":"2022","unstructured":"Nagrani NS, Bhawan J (2022) Histopathological Variants of Cutaneous Neurofibroma: A Compendious Review. Dermatopathol (Basel) 10(1):1\u201319","journal-title":"Dermatopathol (Basel)"},{"issue":"13","key":"5643_CR3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMx200013","volume":"383","author":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","year":"2020","unstructured":"Selumetinib in Children with Inoperable Plexiform Neurofibromas (2020) N Engl J Med 383(13):1290","journal-title":"N Engl J Med"},{"issue":"1","key":"5643_CR4","first-page":"vdaf101","volume":"7","author":"A Adeyemi","year":"2025","unstructured":"Adeyemi A, Gross AM, Baldwin A, Dombi E, Widemann BC, Sint KJ (2025) Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm. Neurooncol Adv 7(1):vdaf101","journal-title":"Neurooncol Adv"},{"issue":"10496","key":"5643_CR5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, Martin S, Farschtschi S, Blanco I et al (2025) Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet 405(10496):2217\u20132230","journal-title":"Lancet"},{"issue":"15","key":"5643_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ et al (2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 382(15):1430\u20131442","journal-title":"N Engl J Med"},{"issue":"12","key":"5643_CR7","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","volume":"26","author":"H Kim","year":"2024","unstructured":"Kim H, Yoon HM, Kim EK, Ra YS, Kim HW, Yum MS et al (2024) Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol 26(12):2352\u20132363","journal-title":"Neuro Oncol"},{"issue":"6","key":"5643_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D et al (2025) ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. J Clin Oncol 43(6):716\u2013729","journal-title":"J Clin Oncol"},{"issue":"2 Suppl 1","key":"5643_CR9","first-page":"S5","volume":"91","author":"N Ortonne","year":"2018","unstructured":"Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM et al (2018) Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology 91(2 Suppl 1):S5\u2013S13","journal-title":"Neurology"},{"issue":"10","key":"5643_CR10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/1346-8138.17888","volume":"52","author":"M Koga","year":"2025","unstructured":"Koga M, Yoshinaga A, Ehara Y, Tsuge I, Yoshida Y, Takagi S et al (2025) A Retrospective Study of Diffuse Plexiform Neurofibroma With Surgical Intervention in Neurofibromatosis 1. J Dermatol 52(10):1589\u20131592","journal-title":"J Dermatol"},{"key":"5643_CR11","unstructured":"Friedman JM (1993) Neurofibromatosis 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A (eds). GeneReviews((R)). Seattle (WA)"},{"issue":"11","key":"5643_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S et al (2022) Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol 24(11):1827\u20131844","journal-title":"Neuro Oncol"},{"issue":"8","key":"5643_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y et al (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23(8):1506\u20131513","journal-title":"Genet Med"},{"key":"5643_CR14","unstructured":"Hockenberry MJRC, Wilson D (2022) Wong\u2019s essentials of pediatric nursing. 11th edn. St. Louis, Missouri: Elsevier"},{"issue":"1","key":"5643_CR15","first-page":"15","volume":"30","author":"DJOJ Yun","year":"2012","unstructured":"Yun DJOJ, Kim BJ, Lim JG, Bae JS, Jeong D, Joo IS, Park MS, Kim BJ (2012) Development of Korean Neuropathic Pain Questionnaire for Neuropathic Pain Screening and Grading: A Pilot Stud. J Korean Neurol Assoc 30(1):15\u201325","journal-title":"J Korean Neurol Assoc"},{"issue":"8","key":"5643_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS (2001) PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 39(8):800\u2013812","journal-title":"Med Care"},{"issue":"1","key":"5643_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-017-0607-y","volume":"15","author":"RE Ferner","year":"2017","unstructured":"Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK et al (2017) Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. Health Qual Life Outcomes 15(1):34","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"5643_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N et al (2007) NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68(9):643\u2013647","journal-title":"Neurology"},{"issue":"6","key":"5643_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/neuonc\/nos076","volume":"14","author":"MJ Fisher","year":"2012","unstructured":"Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ et al (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14(6):790\u2013797","journal-title":"Neuro Oncol"},{"issue":"5","key":"5643_CR20","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2214\/ajr.184.5.01841711","volume":"184","author":"GS Huang","year":"2005","unstructured":"Huang GS, Huang CW, Lee HS, Chang WC, Lee CH, Leu NH et al (2005) On the AJR viewbox. Diffuse neurofibroma of the arm: MR characteristics. AJR Am J Roentgenol 184(5):1711\u20131712","journal-title":"AJR Am J Roentgenol"},{"issue":"21 Suppl 1","key":"5643_CR21","first-page":"S33","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG et al (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81(21 Suppl 1):S33\u201340","journal-title":"Neurology"},{"issue":"6","key":"5643_CR22","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","volume":"21","author":"C Erker","year":"2020","unstructured":"Erker C, Tamrazi B, Poussaint TY, Mueller S, Mata-Mbemba D, Franceschi E et al (2020) Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e317\u2013e29","journal-title":"Lancet Oncol"},{"issue":"6","key":"5643_CR23","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hernaiz Driever P, Bag AK, de Blank P, Kadom N et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e305\u2013e16","journal-title":"Lancet Oncol"},{"issue":"1","key":"5643_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/0974-7753.66919","volume":"2","author":"BS Kumar","year":"2010","unstructured":"Kumar BS, Gopal M, Talwar A, Ramesh M (2010) Diffuse neurofibroma of the scalp presenting as circumscribed alopecic patch. Int J Trichology 2(1):60\u201362","journal-title":"Int J Trichology"},{"issue":"1","key":"5643_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","volume":"31","author":"AM Gross","year":"2025","unstructured":"Gross AM, O\u2019Sullivan Coyne G, Dombi E, Tibery C, Herrick WG, Martin S et al (2025) Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med 31(1):105\u2013115","journal-title":"Nat Med"},{"issue":"9","key":"5643_CR26","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","volume":"27","author":"J Fangusaro","year":"2025","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Lensing S, Ligon AH, Lindeman N et al (2025) A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4. Neuro Oncol 27(9):2415\u20132428","journal-title":"Neuro Oncol"},{"issue":"1","key":"5643_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13023-018-0811-9","volume":"13","author":"L Sellmer","year":"2018","unstructured":"Sellmer L, Farschtschi S, Marangoni M, Heran MKS, Birch P, Wenzel R et al (2018) Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis 13(1):62","journal-title":"Orphanet J Rare Dis"},{"key":"5643_CR28","doi-asserted-by":"crossref","unstructured":"Melloni G, Eoli M, Cesaretti C, Bianchessi D, Ibba MC, Esposito S et al (2019) Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. Cancers (Basel) 11(12)","DOI":"10.3390\/cancers11121838"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05643-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:40:30Z","timestamp":1781012430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05643-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5643"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05643-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9255883\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and all methods were carried out in accordance with relevant guidelines and regulations. The study protocol was approved by the Institutional Review Board of Asan Medical Center (Approval No. 2019\u2009\u2212\u20090199). Written informed consent was obtained from all participants and\/or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}